| 【Company Research】BYD (1211 HK/002594 CH) - 4Q24 margins lay foundation for FY25 earnings |
| 【公司研究】贝克微 (2149 HK) - FY24净利率达28.8%，彰显公司强劲盈利能力 |
| 【Company Research】BaTeLab (2149 HK) - Record-high FY24 NPM of 28.8% underpins ability to maintain high margins |
| 【Company Research】ZhongAn (6060 HK) - Tech export out of the red; ZA Bank on track for breakeven |
| 【Company Research】Ping An (2318 HK) - Life OPAT awaits for longer time to turnaround |
| 【Company Research】Hansoh Pharma (3692 HK) - Overseas out-licensing as a sustainable profit driver |
| 【Company Research】Xunfei Healthcare (2506 HK) - Leading the healthcare AI revolution; Initiate with BUY |
| 【Company Research】Baozun (BZUN US) - Driving quality growth |
| 【Company Research】CGN Mining (1164 HK) - Further downside risk should be reduced with large contract/spot uranium price gap |
| 【Company Research】Meituan (3690 HK) - Solid core business earnings growth to provide support for overseas expansion |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
